Company Coverage
CSPC Pharmaceutical Group (1093 HK): 9M26: Results Beat; Targets Positive Revenue Growth In 2027
BUY (Maintained)
Current price:
Target price:
Upside:
Previous TP :
HK$7.99
HK$10.00
25.2%
HK$11.50
Analyst
Analyst
Highlights
- CSPC’s 9M26 results beat expectations with revenue up 27.0% yoy to Rmb25.3b and underlying net profit surging 134.5% yoy to Rmb7.2b. In 3Q26, product sales grew 10.1% yoy, offsetting a 19.9% yoy fall in licence fee income.
- CSPC targets positive revenue growth in 2027, supported by continued innovative product launches and globalisation efforts. We foresee limited revenue growth visibility given the unpredictable timing of licensing income.
- Maintain BUY with a lower target price of HK$10.00 on limited 2027 growth visibility.

Analysis
- 9M26 results beat. CSPC Pharmaceutical Group’s (CSPC) 9M26 revenue rose 27.0% yoy to Rmb25.3b and underlying net profit jumped 134.5% yoy to Rmb7.2b, ahead of our expectations. In 3Q26, revenue rose 0.7% yoy to Rmb6.7b and underlying net profit grew 39.0% yoy to Rmb1,055m.

Highlights
- CSPC’s 9M26 results beat expectations with revenue up 27.0% yoy to Rmb25.3b and underlying net profit surging 134.5% yoy to Rmb7.2b. In 3Q26, product sales grew 10.1% yoy, offsetting a 19.9% yoy fall in licence fee income.
- CSPC targets positive revenue growth in 2027, supported by continued innovative product launches and globalisation efforts. We foresee limited revenue growth visibility given the unpredictable timing of licensing income.
- Maintain BUY with a lower target price of HK$10.00 on limited 2027 growth visibility.

Analysis
- 9M26 results beat. CSPC Pharmaceutical Group’s (CSPC) 9M26 revenue rose 27.0% yoy to Rmb25.3b and underlying net profit jumped 134.5% yoy to Rmb7.2b, ahead of our expectations. In 3Q26, revenue rose 0.7% yoy to Rmb6.7b and underlying net profit grew 39.0% yoy to Rmb1,055m.

BUY (Maintained)
Current price:
Target price:
Upside:
Previous TP :
HK$7.99
HK$10.00
25.2%
HK$11.50
Analyst
Analyst
IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS
This report is provided subject to, and must be read together with, the full Disclosures / Disclaimers available at this link, which are incorporated by reference into this report. In particular, this report is intended for general circulation and informational purposes only and does not constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report. By accessing, receiving or using this report, you acknowledge that you have read, understood and agreed to be bound by the Disclosures / Disclaimers, as may be amended, supplemented or updated from time to time.
Related articles

18 Nov 2026
JD.com (9618 HK): 3Q26: Operating Beat On Margin Expansion And FD Loss Reduction; Retail Returns To Growth

30 Oct 2026
Midea Group (000333 CH): 3Q26: EBIT Declines 3%; Targets Positive Sales Growth For 4Q26

29 Oct 2026
CSPC Innovation Pharmaceutical Co (300765 CH): 3Q26: Swings Back To A Net Loss; Late-Stage Pipeline Gathers Pace
Our latest research

18 Nov 2026
Miniso (MNSO US/9896 HK): 3Q26: Results Better Than Expected; Reiterates 2026 Guidance; Optimistic About Domestic Market In 2027

18 Nov 2026
JD.com (9618 HK): 3Q26: Operating Beat On Margin Expansion And FD Loss Reduction; Retail Returns To Growth

18 Nov 2026
